Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment

The Parkinson's Disease market is rapidly evolving with cutting-edge research and breakthrough therapies, driven by leading companies like ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, and Kallyope. These innovators are revolutionizing treatment approaches and shaping the future of Parkinson's disease care, offering new hope for patients worldwide.

DelveInsight's 'Parkinson's Disease Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Parkinson's Disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Parkinson's Disease pipeline domain.

For emerging Parkinson's Disease drugs, the Parkinson's Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's Disease Pipeline analysis depicts a robust space with 130+ active players working to develop 150+ pipeline drugs for Parkinson's Disease treatment.
• The leading Parkinson's Disease companies include Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others are evaluating their lead assets to improve the Parkinson's Disease treatment landscape.
• Key Parkinson's Disease pipeline therapies in various stages of development include Solengepras (CVN424), Minzasolmin (UCB0599), Buntanetap (ANVS401/Posiphen), SPN-830 (Apomorphine Infusion), P2B001 (Extended-release Pramipexole and Rasagiline), ND0612 (Levodopa/Carbidopa), Tavapadon, Prasinezumab, Risvodetinib, GT 02287, NNI 362, and others.
• In March 2025, MeiraGTx and Hologen will launch a joint venture, Hologen Neuro AI Ltd, with Hologen committing $230 million to fully fund the development of AAV-GAD for Parkinson's disease through commercialization, along with other potential pipeline products. This collaboration leverages MeiraGTx's expertise in genetic medicine and Hologen's AI-driven clinical data models for drug development.
• In March 2025, MedRhythms announced that MR-005, its neurorehabilitation system designed to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been classified as a Class II, Rx-only medical device by the U.S. Food and Drug Administration (FDA). The system will be marketed under the brand name Movive.
• In Feb 2025, Medtronic plc, a global leader in healthcare technology, announced the FDA approval of BrainSenseTM Adaptive deep brain stimulation (aDBS) and BrainSenseTM Electrode Identifier (EI). While there is no cure for debilitating neurological conditions like Parkinson's, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson's and other neurological disorders for over 30 years.
• In February 2025, AB-1005, AskBio's investigational gene therapy for Parkinson's disease, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA to accelerate its development and review for treating serious or life-threatening conditions.
• In February 2025, the U.S. FDA approved Ctexli (chenodiol) for treating cerebrotendinous xanthomatosis (CTX) in adults, making it the first FDA-approved drug for this rare lipid storage disease.
• In February 2025, Newronika received FDA Investigational Device Exemption (IDE) clearance to begin a pivotal U.S. clinical trial. The trial will assess the safety and efficacy of its adaptive deep brain stimulation system for patients with movement disorders, including Parkinson's disease.
• In February 2025, Supernus Pharmaceuticals, Inc. announced that the U.S. FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for treating motor fluctuations in adults with advanced Parkinson's disease.

Request a sample and discover the recent breakthroughs happening in the Parkinson's Disease pipeline landscape @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Parkinson's Disease Overview
Parkinson's disease (PD) is a chronic, progressive neurological disorder that primarily affects movement control due to the gradual degeneration of dopamine-producing neurons in the substantia nigra. It is the second most common neurodegenerative disease after Alzheimer's disease, typically affecting individuals over 60, though early-onset Parkinson's disease can also occur. The progression of Parkinson's disease symptoms varies widely among patients, making it difficult to predict and manage effectively.

The hallmark symptoms of Parkinson's disease include tremors, bradykinesia (slowness of movement), muscle rigidity, and postural instability. Tremors often begin in the hands or fingers at rest, while bradykinesia significantly impacts daily activities. Muscle stiffness leads to discomfort and restricted movement, while postural instability increases the risk of falls. Additionally, non-motor symptoms of Parkinson's disease, such as sleep disturbances, depression, anxiety, cognitive impairment, and autonomic dysfunction, further contribute to disease burden. While the exact cause of Parkinson's disease remains unclear, it is believed to result from a combination of genetic and environmental factors, including LRRK2 and SNCA gene mutations and exposure to pesticides or heavy metals. The disease is characterized by alpha-synuclein protein aggregation, forming Lewy bodies, which disrupt dopamine neurotransmission.

Diagnosis is primarily clinical, relying on neurological evaluation and medical history, as no definitive laboratory test exists. However, DaTscan imaging may help detect reduced dopamine transporter activity. Parkinson's disease treatment focuses on symptom management, as no Parkinson's disease cure currently exists. Levodopa remains the most effective medication, while dopamine agonists and MAO-B inhibitors are also widely used. In advanced cases, deep brain stimulation (DBS) can offer significant symptom relief. Additionally, physical therapy, occupational therapy, and lifestyle modifications play a crucial role in improving the quality of life for Parkinson's disease patients.

Find out more about Parkinson's Disease medication @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Parkinson's Disease Treatment Analysis: Drug Profile
Buntanetap: Annovis Bio
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby restoring brain function and improving patients' quality of life. Currently, the drug is in a Phase III trial for the treatment of Parkinson's disease.

Tavapadon: Cerevel Therapeutics
Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson's disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD. Tavapadon is designed to selectively and optimally activate D1/D5 receptors to potentially provide the right balance of motor control, safety and tolerability for patients. By selectively activating D1/D5 dopamine receptors along the nigrostriatal pathway, tavapadon has the potential to offer the right balance of dopamine signaling to improve motor control while avoiding D2/D3 overstimulation, which is believed to underlie many of the side effects of current dopamine agonists. Additionally, as a partial agonist with a 24-hour half-life enabling once-daily dosing, tavapadon may avoid hyper activation of the dopamine receptors, which can lead to troublesome dyskinesias. Currently, the drug is in Phase III trial for the treatment of Parkinson's disease.

Prasinezumab: Roche
Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson's disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. Currently, the drug is in Phase II trial for the treatment of Parkinson's disease.

Risvodetinib: Inhibikase Therapeutics, Inc
Risvodetinib (IkT-148009), is a potent, selective small-molecule designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson's disease, with the goal of halting disease progression and reversing functional loss. Risvodetinib (IkT-148009) is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. Currently, the drug is in Phase II trial for the treatment of Parkinson's disease.

Key Parkinson's Disease Therapies and Companies
• Solengepras (CVN424): Cerevance
• Minzasolmin (UCB0599): UCB Biopharma SRL/Novartis
• Buntanetap (ANVS401/Posiphen): Annovis Bio
• SPN-830 (Apomorphine Infusion): Supernus Pharmaceuticals, Inc./ Britannia Pharmaceutical
• P2B001 (Extended-release Pramipexole and Rasagiline): Pharma Two B
• ND0612 (Levodopa/Carbidopa): Mitsubishi Tanabe Pharma (NeuroDerm)
• Tavapadon: AbbVie/Cerevel Therapeutics, LLC
• Prasinezumab: Roche
• Risvodetinib: Inhibikase Therapeutics, Inc
• GT 02287: Gain Therapeutics
• NNI 362: Neuronascent

Learn more about the novel and emerging Parkinson's Disease pipeline therapies @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Parkinson's Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Parkinson's Disease Pipeline Report
• Coverage: Global
• Key Parkinson's Disease Companies: Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others.
• Key Parkinson's Disease Pipeline Therapies: Solengepras (CVN424), Minzasolmin (UCB0599), Buntanetap (ANVS401/Posiphen), SPN-830 (Apomorphine Infusion), P2B001 (Extended-release Pramipexole and Rasagiline), ND0612 (Levodopa/Carbidopa), Tavapadon, Prasinezumab, Risvodetinib, GT 02287, NNI 362, and others.

Dive deep into rich insights for drugs used for Parkinson's Disease treatment; visit @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Parkinson's Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Parkinson's Disease Pipeline Therapeutics
6. Parkinson's Disease Pipeline: Late-Stage Products (Phase III)
7. Parkinson's Disease Pipeline: Late-Stage Products (Phase III)
8. Parkinson's Disease Pipeline: Mid-Stage Products (Phase II)
9. Parkinson's Disease Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.